Search Results - "Migden, Michael"

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial by Stratigos, Alexander J, Sekulic, Aleksandar, Peris, Ketty, Bechter, Oliver, Prey, Sorilla, Kaatz, Martin, Lewis, Karl D, Basset-Seguin, Nicole, Chang, Anne Lynn S, Dalle, Stèphane, Orland, Almudena Fernandez, Licitra, Lisa, Robert, Caroline, Ulrich, Claas, Hauschild, Axel, Migden, Michael R, Dummer, Reinhard, Li, Siyu, Yoo, Suk-Young, Mohan, Kosalai, Coates, Ebony, Jankovic, Vladimir, Fiaschi, Nathalie, Okoye, Emmanuel, Bassukas, Ioannis D, Loquai, Carmen, De Giorgi, Vincenzo, Eroglu, Zeynep, Gutzmer, Ralf, Ulrich, Jens, Puig, Susana, Seebach, Frank, Thurston, Gavin, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Bowler, Timothy, Fury, Matthew G

“…Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy…”
Get full text

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma by Sharpe, Hayley J., Pau, Gregoire, Dijkgraaf, Gerrit J., Basset-Seguin, Nicole, Modrusan, Zora, Januario, Thomas, Tsui, Vickie, Durham, Alison B., Dlugosz, Andrzej A., Haverty, Peter M., Bourgon, Richard, Tang, Jean Y., Sarin, Kavita Y., Dirix, Luc, Fisher, David C., Rudin, Charles M., Sofen, Howard, Migden, Michael R., Yauch, Robert L., de Sauvage, Frederic J.

“…Smoothened (SMO) inhibitors are under clinical investigation for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced…”
Get full text

Stasis Dermatitis: Pathophysiology, Evaluation, and Management by Sundaresan, Swaminathan, Migden, Michael R., Silapunt, Sirunya

“…Stasis dermatitis commonly occurs in older age. It is caused by venous hypertension resulting from retrograde flow due to incompetent venous valves, valve…”
Get full text

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study by Sekulic, Aleksandar, Migden, Michael R, Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D, Miller, Chris, Mortier, Laurent, Murrell, Dedee F, Hamid, Omid, Quevedo, Jorge F, Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel

“…In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective…”
Get full text

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial by Migden, Michael R, Khushalani, Nikhil I, Chang, Anne Lynn S, Lewis, Karl D, Schmults, Chrysalyne D, Hernandez-Aya, Leonel, Meier, Friedegund, Schadendorf, Dirk, Guminski, Alexander, Hauschild, Axel, Wong, Deborah J, Daniels, Gregory A, Berking, Carola, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G, Rischin, Danny

“…Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous…”
Get full text

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial by Migden, Michael R, Dr, Guminski, Alexander, PhD, Gutzmer, Ralf, Prof, Dirix, Luc, MD, Lewis, Karl D, MD, Combemale, Patrick, MD, Herd, Robert M, MD, Kudchadkar, Ragini, MD, Trefzer, Uwe, Prof, Gogov, Sven, MD, Pallaud, Celine, PhD, Yi, Tingting, PhD, Mone, Manisha, PhD, Kaatz, Martin, MD, Loquai, Carmen, MD, Stratigos, Alexander J, Prof, Schulze, Hans-Joachim, MD, Plummer, Ruth, Prof, Chang, Anne Lynn S, MD, Cornélis, Frank, MD, Lear, John T, MD, Sellami, Dalila, MD, Dummer, Reinhard, Prof

“…Summary Background Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around…”
Get full text

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma by Sekulic, Aleksandar, Migden, Michael R, Oro, Anthony E, Dirix, Luc, Lewis, Karl D, Hainsworth, John D, Solomon, James A, Yoo, Simon, Arron, Sarah T, Friedlander, Philip A, Marmur, Ellen, Rudin, Charles M, Chang, Anne Lynn S, Low, Jennifer A, Mackey, Howard M, Yauch, Robert L, Graham, Richard A, Reddy, Josina C, Hauschild, Axel

“…In this international, nonrandomized study, vismodegib, an oral inhibitor of the ligand that activates the hedgehog pathway, showed responses in patients with…”
Get full text

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma by Migden, Michael R, Rischin, Danny, Schmults, Chrysalyne D, Guminski, Alexander, Hauschild, Axel, Lewis, Karl D, Chung, Christine H, Hernandez-Aya, Leonel, Lim, Annette M, Chang, Anne Lynn S, Rabinowits, Guilherme, Thai, Alesha A, Dunn, Lara A, Hughes, Brett G.M, Khushalani, Nikhil I, Modi, Badri, Schadendorf, Dirk, Gao, Bo, Seebach, Frank, Li, Siyu, Li, Jingjin, Mathias, Melissa, Booth, Jocelyn, Mohan, Kosalai, Stankevich, Elizabeth, Babiker, Hani M, Brana, Irene, Gil-Martin, Marta, Homsi, Jade, Johnson, Melissa L, Moreno, Victor, Niu, Jiaxin, Owonikoko, Taofeek K, Papadopoulos, Kyriakos P, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G

“…Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was…”
Get full text

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC by Sekulic, Aleksandar, MD, Migden, Michael R., MD, Lewis, Karl, MD, Hainsworth, John D., MD, Solomon, James A., MD, PhD, Yoo, Simon, MD, Arron, Sarah T., MD, PhD, Friedlander, Philip A., MD, PhD, Marmur, Ellen, MD, Rudin, Charles M., MD, PhD, Chang, Anne Lynn S., MD, Dirix, Luc, MD, PhD, Hou, Jeannie, MD, Yue, Huibin, PhD, Hauschild, Axel, MD

“…Background Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of…”
Get full text

How We Do It: A Systematic Approach to Reapproximating the Terminal Medial Brow During Forehead Flap Reconstruction by Gali, Linna L., Lazaroff, Jake M., Migden, Michael R.

Get full text

Treatments on the horizon for locally advanced basal cell carcinoma by Idriss, Munir H., Stull, Carolyn M., Migden, Michael R.

“…Basal cell carcinoma (BCC) is one of the most common human cancers. Most cases of BCC are amenable to surgical and topical treatments with excellent prognosis…”
Get full text

Emerging trends in the treatment of advanced basal cell carcinoma by Migden, Michael R., Chang, Anne Lynn S., Dirix, Luc, Stratigos, Alexander J., Lear, John T.

“…•Outcomes for patients with advanced basal cell carcinoma (BCC) are relatively poor.•Hedgehog pathway inhibitors are a promising treatment option for advanced…”
Get full text

Current and emerging intralesional immunotherapies in cutaneous oncology by Stull, Carolyn M., Clark, Denise, Parker, Tayler, Idriss, Munir H., Patel, Vishal A., Migden, Michael R.

“…Immunotherapies have revolutionized the management of advanced cutaneous malignancies. However, some patients fail to respond to these therapies, others are…”
Get full text

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma by Dummer, Reinhard, MD, Guminski, Alexander, MD, PhD, Gutzmer, Ralf, MD, Dirix, Luc, MD, Lewis, Karl D., MD, Combemale, Patrick, MD, Herd, Robert M., MD, Kaatz, Martin, MD, Loquai, Carmen, MD, Stratigos, Alexander J., MD, Schulze, Hans-Joachim, MD, Plummer, Ruth, MD, Gogov, Sven, MD, Pallaud, Celine, PhD, Yi, Tingting, PhD, Mone, Manisha, PhD, Chang, Anne Lynn S., MD, Cornélis, Frank, MD, Kudchadkar, Ragini, MD, Trefzer, Uwe, MD, Lear, John T., MD, Sellami, Dalila, MD, Migden, Michael R., MD

“…Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell…”
Get full text

Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer by Chen, Leon, Aria, Alexander B, Silapunt, Sirunya, Migden, Michael R

“…BACKGROUNDLocally advanced and metastatic nonmelanoma skin cancer (NMSC) not amenable to surgical resection requires a different approach to therapy…”
Get full text

Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma by Aboul-Fettouh, Nader, Chen, Leon, Silapunt, Sirunya, Migden, Michael R.

Get full text

Do Not Mess With Tattoos? Mohs Micrographic Surgery for Basal Cell Carcinoma Within the State of Texas by Aboul-Fettouh, Nader, Patel, Jigar, Migden, Michael R

Get full text

Venous Treatment of Lipodermatosclerosis to Improve Ambulatory Function by Balasubramanyam, Sadhana, Migden, Michael R, Silapunt, Sirunya

Get full text

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing by Rischin, Danny, Migden, Michael R, Lim, Annette M, Schmults, Chrysalyne D, Khushalani, Nikhil I, Hughes, Brett G M, Schadendorf, Dirk, Dunn, Lara A, Hernandez-Aya, Leonel, Chang, Anne Lynn S, Modi, Badri, Hauschild, Axel, Ulrich, Claas, Eigentler, Thomas, Stein, Brian, Pavlick, Anna C, Geiger, Jessica L, Gutzmer, Ralf, Alam, Murad, Okoye, Emmanuel, Mathias, Melissa, Jankovic, Vladimir, Stankevich, Elizabeth, Booth, Jocelyn, Li, Siyu, Lowy, Israel, Fury, Matthew G, Guminski, Alexander

“…BackgroundCemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase…”
Get full text

The Use of a Dehydrated Complete Human Placental Membrane Allograft for Mohs Surgical Defects of the Nose by Wilmas, Kelly M., Patel, Jigar, Silapunt, Sirunya, Doan, Hung Q., Migden, Michael R.

“…Repair options for Mohs surgical defects include primary closure, flap or graft, or healing by second intention. These options may not be optimal in all cases…”
Get full text